

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1625

In re Application of:

Jorg-Thorsten MOHR et al.

Serial No.: 09/640,748

Group Art Unit: 1625

Filed: 18 August 2000

Examiner: Ba K. Trinh

For: PROCESS FOR PRODUCTION OF DROSPIRENONE AND INTERMEDIATE

PRODUCTS OF THE PROCESS

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

This information disclosure statement is made in accordance with 37 C.F.R. §§ 1.56, 1.97 and 1.98 as follows:

Timing and Fees

| | losure statement is filed: | | | | | |
|---|---|---|--|--|--|--|
| | | three months of the filing date of a national application other than a CPA § 1.53(d); | | | | |
| | | three months of the actual filing date of the national phase of a PCT ration; OR | | | | |
| | before the mailing of a first substantive office action (including after filing of an RCE). | | | | | |
| Under 37 C.F.R. § 1.97(c), this information disclosure statement is filed after the periodecified in 37 C.F.R. § 1.97(b), but before the mailing date of: | | | | | | |
| | | a final rejection under 37 C.F.R. 1.113; | | | | |
| | | termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR | | | | |
| | | a notice of allowance under 37 C.F.R. § 1.311; and | | | | |

1

| | is accompanied by: | | | | | |
|---------------|--------------------|--|--|--|--|--|
| | | the statement as specified in 37 C.F.R. § 1.97(e) set out below; OR | | | | |
| | | a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p). | | | | |
| | | S.R. § 1.97(d), this information disclosure statement is filed after the mailing statement actions which have not been withdrawn: | | | | |
| | | a final action under 37 C.F.R. § 1.113; | | | | |
| | | termination of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2); OR | | | | |
| | \boxtimes | a notice of allowance under 37 C.F.R. § 1.311; | | | | |
| AND | is filed | on or before payment of the issue fee; AND is accompanied by: | | | | |
| | \boxtimes | the statement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of \$180.00 under 37 C.F.R. § 1.17(p). | | | | |
| Statements U | nder 37 | C.F.R. 1.97(e) | | | | |
| | \boxtimes | Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or | | | | |
| | | No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement. | | | | |
| Cited Materia | ıls | | | | | |
| | ancest | or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d). | | | | |
| \boxtimes | Copies dated] | s of materials listed and attached were cited in a European search report 1 October 2004. | | | | |

| | | Copies of the materials listed are attached (except for the foregoing). |
|--------------|----------------|---|
| Non-E | nglish l | Language References |
| | | An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s). |
| | \boxtimes | A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below: |
| | | X = document of particular relevance when it is taken alone Y = document of particular relevance when it is combined with another such document A = document defining the general state of the art O = non-written disclosure P = intercalated document T = document cited to understand the theory or principle underlying the invention E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date D = cited in the application L = cited for another reason & = publication of member of same patent family |
| | \boxtimes | Translation of other relevant information on foreign search report |
| | | In the search report, "Seite" means page, "Seiten" means pages, "Verbindungen der Formel" means Figure of formula, "Beispele" means examples, and "das ganze Dokument" means the entire document, "Spalte" means column, "Zeile" means line, "Abbildungen" means claims, "Anspruch" means example, "Zusammenfassung" means summary, and "Tabelle" means table, and "Tabellen" means tables "in der Anmeldung erwaehnt" means cited in the application, "Schema" means scheme, "und" means and, "Absatz" means break, "Abildung" means figure. |
| Other | <u>Informa</u> | <u>ition</u> |
| <u>Payme</u> | nt of Fe | ees Due (If Any): |
| \boxtimes | A chec | ck for \$180 covering the fee identified above is attached. |
| | Please | charge to Deposit Account No. 13-3402 \$ for the fee identified above. |

The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Csaba Henter, Reg. No. 50,908

Attorney for Applicants

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1664-C1

Date: December 23, 2004

CH:at

K:\Sch\1664\C1\Information Disclosure Statement.doc

Please type a plus sign (+) inside this box

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

PADEMARI TRADEMARI Under the Paperwork Reduction Act of 1995, no person tured to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet of

| Complete if Known | | | | |
|------------------------|---------------------------|--|--|--|
| Application Number | 09/640,748 | | | |
| Filing Date | 18 August 2000 | | | |
| First Named Inventor | Jorg-Thorsten MOHR et al. | | | |
| Group Art Unit | 1625 | | | |
| Examiner Name | Ba K. Trinh | | | |
| Attorney Docket Number | SCH-1664-C01 | | | |

| | U.S. PATENT DOCUMENTS | | | | | | |
|------------------------|-----------------------|-------------------|--|---|---|--|--|
| Examiner Initials * | Cite No.1 | U.S. Patent Docur | nent Kind Code ² (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | | |
| | 1 | 4,129,564 | | WIECHERT et al. | 12-12-1978 | | |
| | 2 | 4,435,327 | | PETZOLDT et al. | 03-06-1984 | | |
| | 3 | 4,614,616 | | PETZOLDT et al. | 09-30-1986 | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | _ | | | | | | |

| ľ | Cite No.1 | Foreign Patent Document | | | 5 | Pages, Columns, Lines, | | |
|-----------------------|-----------|-------------------------|----------|--------------------------------------|--|--|--|----------------|
| Examiner Initials* | | Office ³ | Number⁴ | Kind Code ⁵ (if known) | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document MM-DD-YYYY | Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | 2 | DE | 3626838 | | Schering AG | 02-11-1988 | | |
| | 3 | DE | 2652761 | | Schering AG | 05-18-1978 | | 1 |
| | 4 | EP | 0075189 | | Schering AG | 03-30-1983 | | 2 |
| | 5 | EP | 0051143 | | Schering AG | 05-12-1982 | | 3 |
| | 6 | wo | 90/14344 | | GAF Chemical Corp. | 11-29-1990 | | - |

| Examiner | Date |
|-----------|------------|
| Signature | Considered |

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached. Number refers to English language corresponding family member.



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO Complete if Known **Application Number** 09/640,748 INFORMATION DISCLOSURE Filing Date 18 August 2000 STATEMENT BY APPLICANT First Named Inventor Jorg-Thorsten MOHR et al. Group Art Unit 1625 (use as many sheets as necessary) **Examiner Name** Ba K. Trinh Sheet of Attorney Docket Number SCH-1664-C01

| NON PATENT LITERATURE DOCUMENTS | | | | | |
|---------------------------------|---------------|--|-----|--|--|
| Examiner Initials * | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T 2 | | |
| | 7 | NICKISCH K ET AL., "Acid catalyzed rearrangements of 15-beta 16-beta methylene-17-alpha-pregnene-21 17-carbolactone derivatives," Tetrahedron Letters, 1986, pages 5463-5466, vol. 27, no. 45, XP002298941, ISSN: 0040-4039; page 5463, abstract 2- page 5464, abstract 1. | | | |
| | 8 | BITTLER D ET AL., "Synthesis of spirorenone – a novel highly active aldosterone antagonist," Angewandte Chemie. International Edition, Verlag Chemie. Weinheim, DE, 1982, pages 696-697, vol. 21, no. 9, XP002047531, ISSN: 0570-0833; page 696, split 2, illustration 1. | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | . | | | | |
| | | | | | |
| - | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |

| Examiner | Date | |
|-----------|------------|--|
| Signature | Considered | |
| 0.3 | Oonsidered | |

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.